Major drug manufacturer Eli Lilly’s new weight loss drug Zepbound is now available for purchase in U.S. pharmacies, the company announced Tuesday.
The recently-approved Zepbound is a once-weekly injection with steady dosage increases over a 20-week period that purportedly makes users feel fuller for longer, subsequently decreasing their food intake.
Zepbound’s launch comes as other blockbuster weight loss drugs like Ozempic, Wegovy and Mounjaro face nationwide shortages.
Wall Street has predicted the weight loss drug industry to reach $100 billion by 2030.
